The 2014 ASCO Gastrointestinal (GI) Cancer Symposium takes place in San Francisco from Jan 16-18 and is the second meeting in this year’s oncology conference calendar. GI cancers include oesophageal, gastric, colorectal and pancreatic cancers, as well as hepatocarcinoma or HCC (liver).
You can follow any tweets from ASCO GI using the hashtag #GI14.
This year, the topics that most caught my eye in the program were pancreatic and gastric cancers.
This post provides insights on the key studies that looked interesting to me at this event, based on the schedule available. The abstracts will be available on January 14th and can be accessed here.
Companies mentioned: Celgene, Lilly, Roche/Genentech, Aduro Biotech
Drugs mentioned: Abraxane, Gemzar, ramucirumab, Avastin, Herceptin, GVAX